Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors

Psychonomic Bulletin and Review

Volumn 4, Issue 1, 1997, Pages

  van Wieringen, Jan Peter ^a   Michel, Martin C ^b   Janssen, Henk M ^c   Janssen, Anton G ^d   Elsinga, Philip H ^e   Booij, Jan ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c SyMO Chem   (Netherlands)

^d GE HEALTHCARE   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Dopamine D2 3 receptor; Intracellular signalling; PET SPECT

Indexed keywords

EID: 84930791894     PISSN: 10699384     EISSN: 15315320     Source Type: Journal    
DOI: 10.1186/s13550-014-0053-3     Document Type: Article

References (30)

1. Usiello A, Baik JH, Rouge-Pont F, Picetti R, Dierich A, LeMeur M, Piazza PV, Borrelli E: Distinct functions of the two isoforms of dopamine D2 receptors.Nature 2000, 408:199–203.
2. Jackson DM, Westlinddanielsson A: Dopamine receptors: molecular-biology, biochemistry and behavioral-aspects.Pharmacol Ther 1994, 64:291–370.
3. Sibley DR, De Lean A, Creese I: Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor.J Biol Chem 1982, 257:6351–6361.
4. 11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography.J Neurochem 2006, 97:1089–1103.
5. 11C] raclopride to measure amphetamine-induced dopamine release in the human striatum.J Pharmacol Exp Ther 2010, 333:533–539.
6. 11C]-raclopride.Synapse 2004, 52:188–208.
7. 11C]raclopride sensitivity to acute amphetamine challenge in healthy humans.J Cerebr Blood Flow Metabol 2012, 32:127–136.
8. Laruelle M: Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review.J Cerebr Blood Flow Metabol 2000, 20:423–451.
9. 11C]raclopride.Synapse 2006, 59:260–269.
10. Skinbjerg M, Namkung Y, Halldin C, Innis RB, Sibley DR: Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors.Synapse 2009, 63:462–475.
11. 11C] MNPA.Synapse 2009, 63:378–389.
12. 3H] raclopride are indistinguishably inhibited by D2 agonists and antagonists ex vivo.Nucl Med Biol 2008, 35:11–17.
13. 11C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro.Synapse 2009, 63:998–1009.
14. Michel MC, Alewijnse AE: Ligand-directed signaling: 50 ways to find a lover.Mol Pharmacol 2007, 72:1097–1099.
15. Beaulieu JM, Gainetdinov RR: The physiology, signaling, and pharmacology of dopamine receptors.Pharmacol Rev 2011, 63:182–217.
16. Beaulieu JM, Gainetdinov RR, Caron MG: The Akt-GSK-3 signaling cascade in the actions of dopamine.Trends Pharmacol Sci 2007, 28:166–172.
17. Chen X, Sassano MF, Zheng L, Setola V, Chen M, Bai X, Frye SV, Wetsel WC, Roth BL, Jin J: Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D2 receptor agonists.J Med Chem 2012, 55:7141–7153.
18. Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S, Ydav PN, Huang XP, Feng B, Jensen NH, Che X, Bai X, Frye SV, Wetsel WC, Caron MG, Javitch JA, Roth BL, Jin J: Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.Proc Natl Acad Sci U S A 2011, 108:18488–18493.
19. van Wieringen JP, Shalgunov V, Janssen HM, Fransen PM, Janssen AGM, Michel MC, Booij J, Elsinga PH: Synthesis and characterization of a novel series of agonist compounds as potential radiopharmaceuticals for imaging of dopamine D2/3 receptors in their high-affinity state.J Med Chem 2014, 57:291–410.
20. 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.Mov Disord 1998, 13:438–445.
21. Booij J, Korn P, Linszen DH, van Royen EA: Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography.Eur J Nucl Med 1997, 24:674.
22. Depaulis T, Kumar Y, Johansson L, Ramsby S, Florvall L, Hall H, Angebymoller K, Ogren SO: Potential neuroleptic agents. 3. Chemistry and antidopaminergic properties of substituted 6-methoxysalicylamides.J Med Chem 1985, 28:1263–1269.
23. Skinbjerg M, Liow JS, Seneca N, Hong J, Lu S, Thorsell A, Heilig M, Pike VW, Halldin C, Sibley DR, Innis RB: D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model.Neuroimage 2010, 50:1402–1407.
24. Seeman P: Are dopamine D2 receptors out of control in psychosis?Progr Neuro-Psychopharmacol Biol Psych 2013, 46:146–152.
25. van de Giessen E, Celik F, Schweitzer DH, van den Brink W, Booij J: Dopamine D2/3 receptor availability and amphetamine-induced dopamine release in obesity.J Psychopharmacol 2014, 28:866–873.
26. 11C]raclopride positron emission tomography study in cats.Biol Psychiatry 2004, 55:1188–1194.
27. Guo N, Guo W, Kralikova M, Jiang M, Schieren I, Narendran R, Slifstein M, Abi-Dargham A, Laruelle M, Javitch JA, Rayport S: Impact of D2 receptor internalization on binding affinity of neuroimaging radiotracers.Neuropsychopharmacol 2009, 35:806–817.
28. Free RB, Chun LS, Moritz AE, Miller BN, Doyle TB, Conroy JL, Padron A, Meade JA, Xiao J, Hu X, Dulcey AE, Han Y, Duan L, Titus S, Bryant -Genever M, Barnaeva E, Ferrer M, Javitch JA, Beuming T, Shi L, Southall NT, Marugan JJ, Sibley DR: Discovery and characterization of a G protein-biased agonist that inhibits b-arrestin recruitment to the D2 dopamine receptor.Mol Phamacol 2014, 86:96–105.
29. Hall DA, Strange PG: Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors.Br J Pharmacol 1997, 121:731–736.
30. Rang HP, Dale MM, Ritter JM: How drugs act: general principles. In Pharmacology. 5th edition. Edited by Hunter L. London: Churchill Livingstone; 2003:17.